1. Home
  2. NDLS vs MDCX Comparison

NDLS vs MDCX Comparison

Compare NDLS & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Noodles & Company

NDLS

Noodles & Company

HOLD

Current Price

$14.32

Market Cap

68.7M

ML Signal

HOLD

Logo Medicus Pharma Ltd.

MDCX

Medicus Pharma Ltd.

HOLD

Current Price

$0.17

Market Cap

15.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NDLS
MDCX
Founded
1995
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
68.7M
15.9M
IPO Year
2013
2025

Fundamental Metrics

Financial Performance
Metric
NDLS
MDCX
Price
$14.32
$0.17
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
31.4K
2.8M
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$495,089,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.37
N/A
52 Week Low
$0.47
$0.15
52 Week High
$19.00
$3.05

Technical Indicators

Market Signals
Indicator
NDLS
MDCX
Relative Strength Index (RSI) 43.91 27.42
Support Level $12.83 N/A
Resistance Level $16.10 $0.36
Average True Range (ATR) 0.95 0.02
MACD -0.30 -0.00
Stochastic Oscillator 12.39 13.86

Price Performance

Historical Comparison
NDLS
MDCX

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.

About MDCX Medicus Pharma Ltd.

Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.

Share on Social Networks: